Ayala Pharma - About the company
Ayala Pharma is a public company based in Wilmington (United States), founded in 2017 by Matti Davis and Guy Harmelin. It operates as a Developer of small molecule-based therapeutics for cancer treatment. Ayala Pharma has raised $50.6M in funding from Novartis and Bristol-Myers Squibb. The company has 3297 active competitors, including 1120 funded and 776 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of small molecule-based therapeutics for cancer treatment. The company has developed gamma-secretase inhibitors (GSIs) for use as targeted cancer therapies. These drugs inhibit gamma-secretase which in turn lead to deactivation of the Notch signaling pathway. The company's lead product candidate AL-101 is in Phase-2 clinical trials.
- Website
- ayalapharma.com
- Email ID
- *****@ayalapharma.com
- Phone Number
- +1 **********
- Registered Address
- 1007 North Orange Street, 4th Floor, Wilmington, DE 19801
Key Metrics
Founded Year
2017
Location
Wilmington, United States
Stage
Public
Total Funding
$50.6M in 4 rounds
Latest Funding Round
Ranked
645th among 3297 active competitors
Annual Revenue
$0 - $1M as on Dec 31, 2023
Employee Count
50 - 199 as on Mar 01, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Ayala Pharma
Ayala Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
AYALA PHARMACEUTICALS, INC. CIN: 0001100397 , United States, Active | Nov 13, 2017 | $0 - $1M (As on Dec 31, 2023) | 21 (As on Oct 31, 2023) | - |
Ayala Pharma's IPO details
Ayala Pharma got listed on May 08, 2020.
Click here to take a look at Ayala Pharma's IPO in detail
Sign up to download Ayala Pharma's company profile
Ayala Pharma's funding and investors
Ayala Pharma has raised a total funding of $50.6M over 4 rounds. Its latest funding round was a Post IPO round on Feb 19, 2021 for $*****. 2 investors participated in its latest round. Ayala Pharma has 11 institutional investors.
Here is the list of recent funding rounds of Ayala Pharma:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 19, 2021 | 2000000 | Post IPO | 9229688 | 8861175 | 6777884 | 3437689 |
May 28, 2019 | 9529906 | Series B | 1654951 | 3315999 | 2396669 | |
Dec 25, 2018 | 9441577 | Series A | 8619912 | 6932806 | 6076859 |
Access funding benchmarks and valuations. Sign up today!View details of Ayala Pharma's funding rounds and investors
Ayala Pharma's founders and board of directors
Founder? Claim ProfileThe founders of Ayala Pharma are Matti Davis and Guy Harmelin.
Here are the details of Ayala Pharma's key team members:
- Matti Davis: Co-Founder of Ayala Pharma.
- Guy Harmelin: Co-Founder of Ayala Pharma.
View details of Ayala Pharma's Founder profiles and Board Members
Ayala Pharma's employee count trend
Ayala Pharma has 50 - 199 employees as of Mar 26. Here is Ayala Pharma's employee count trend over the years:
Uncover Ayala Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Ayala Pharma's Competitors and alternates
Top competitors of Ayala Pharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Ayala Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 73/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
645th |  Ayala Pharma 2017, Wilmington (United States), Public | Developer of small molecule-based therapeutics for cancer treatment | $50.6M | 49/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Ayala Pharma's competitors? Click here to see the top ones
Ayala Pharma's Investments and acquisitions
Ayala Pharma has made no investments or acquisitions yet.
Reports related to Ayala Pharma
Here is the latest report on Ayala Pharma's sector:
News related to Ayala Pharma
Filter this listMedia has covered Ayala Pharma for a total of 2 events in the last 1 year.
•
•
•
•
•
•
•
Immunome wins Ayala’s Phase III desmoid tumour candidate for $50mPharmaceutical Technology•Feb 07, 2024•Immunome, Ayala Pharma
•
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger AgreementGlobeNewswire•Jul 27, 2023•Ayala Pharma, BioSight
•
•
Ayala Pharma to continue Phase 2/3 Ringside study in desmoid tumorsSeeking Alpha•Mar 03, 2023•Ayala Pharma
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Ayala Pharma
Explore our recently published companies
- Entekhaabco - Kuwait City based, 2019 founded, Unfunded company
- Glovnetics - Gurugram based, 2022 founded, Unfunded company
- NoBuzz - Pretoria based, 2017 founded, Unfunded company
- Tantrayut - Ambernath based, 2015 founded, Unfunded company
- Ningbo Dayang Technology - Ningbo based, 2010 founded, Unfunded company
- Good Riddance Insect Repellent - Mitcham based, 2014 founded, Unfunded company
